Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Adenocarcinoma

This phase 2 randomized clinical trial assesses the safety and efficacy of durvalumab with and without tremelimumab for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.

Read the full article here

Related Articles